2010 EFNS/PNS副蛋白血症性脱髓鞘神经病指南(第一次修订)
The aim of this guideline is to update the 2006 EFNS/PNS guidelineon management of patients with a demyelinating neuropathy and a paraprotein(paraproteinemic demyelinating neuropathy [PDN]) by review of evidence and expertconsensus. In the absence of adequate evidence, the panel agreed on good practicepoints:
(1) patients with PDN should be investigated for a malignant plasma cell dyscrasia;
(2) a monoclonal gammopathy of undetermined significance is more likely to be causing the neuropathy if it is immunoglobulin (Ig)M, anti-neural antibodies are present, and the clinical phenotype is chronic distal sensory neuropathy;
(3) patients with IgM PDN usually have predominantly distal sensory impairment, prolonged distal motor latencies, and often anti-myelin-associated glycoprotein antibodies;
(4) IgM PDN may respond to immunomodulatory therapies. Their potential benefit should be balanced against possible side effects and the usually slow disease progression;
(5) IgG and IgA PDN may be indistinguishable from chronic inflammatory demyelinating polyradiculoneuropathy; and
(6) Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes syndrome is a multi-system malignant PDN.
展开部分内容仅可在
临床指南app 查看下载
收藏
分享
欧洲神经科协会联盟是获得整个欧洲的神经学家支持的联合组织。目前有44个欧洲国家的神经协会注册会员,注册的神经学家超过19,000名。该学会致力于鼓励欧洲国家的神经系统协会之间的合作,加强基础神经科学和临床神经科学的融合,促进双向转化研究,推进神经病学与发展与神经系统疾病患者的医疗护理。其官方期刊是European Journal of Neurology